Form 4: Lifecore Biomedical Director Matthew Korenberg Receives Significant Equity Grant

Lifecore Biomedical, Inc. Director Matthew E. Korenberg was granted 19,506 restricted stock units, increasing his direct beneficial ownership to 44,060 shares and aligning his interests with long-term shareholder value.

Summary

• Matthew E. Korenberg, a Director of Lifecore Biomedical, Inc. (LFCR), acquired 19,506 restricted stock units (RSUs) on July 15, 2025.
• These RSUs convert into common stock on a one-for-one basis.
• Following this transaction, Mr. Korenberg's direct beneficial ownership of Lifecore Biomedical common stock increased to 44,060 shares.
• The RSUs are subject to a vesting schedule, occurring on the earlier of the one-year anniversary of the grant date (July 15, 2026) or the date of the company's annual meeting of stockholders in calendar year 2026, provided that date is at least 50 weeks from the grant date.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive signal of alignment between management and shareholder interests, and a standard practice for executive compensation. It does not indicate any negative operational or financial news.

Positives

• The grant of restricted stock units to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• Increased direct beneficial ownership by a director demonstrates confidence in the company's future prospects.

Negatives

• The issuance of new restricted stock units could lead to minor future dilution for existing shareholders upon vesting, though this is a standard component of executive compensation.

Risks

• The value of the granted restricted stock units is subject to the future performance of Lifecore Biomedical, Inc.'s stock price.
• The vesting of the RSUs is contingent on continued service as a director until the vesting date.

Future Outlook

The granted restricted stock units are scheduled to vest on the earlier of July 15, 2026, or the date of the company's annual meeting of stockholders in calendar year 2026, subject to a minimum 50-week period from the grant date.

Industry Context

Equity grants, such as restricted stock units, are a common form of compensation for directors and executives across various industries, including the biomedical sector. This practice aims to align the interests of company leadership with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice for compensating board members in publicly traded companies, including those in the biotechnology and medical device sectors.
• Companies like Medtronic (MDT), Boston Scientific (BSX), and Stryker (SYK) frequently utilize equity-based compensation for their non-employee directors to foster long-term alignment and retention.
• The vesting schedule, typically over one year or tied to the next annual meeting, is also common for director equity awards, ensuring continued engagement.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of 19,506 restricted stock units to Matthew E. Korenberg, a Director of Lifecore Biomedical, Inc., which constitutes a related party transaction as it is compensation provided to a member of the board.

Stakeholder Impact

• Shareholders: Potential minor future dilution upon vesting of RSUs, but improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of the 19,506 restricted stock units on or after July 15, 2026.
• Potential conversion of restricted stock units into common stock upon vesting.

Key Dates

Recommendation

Keywords

Lifecore Biomedical, LFCR, Matthew Korenberg, Director, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, Form 4, Beneficial Ownership, Corporate Governance